2025 AXS CME Symposium - Best Practices for Managing Hyperkalemia in Patients with Heart Failure and Chronic Kidney Disease

HAZLET, N.J. - March 10, 2025 - PRLog -- In this educational initiative, to take place at the 2025 AXS Specialty Pharmacy meeting, a multidisciplinary faculty—consisting of two hyperkalemia experts in heart failure (one cardiologist, Dr. Stephen Greene and one pharmacist, Dr. Robert Page) and two hyperkalemia experts in chronic kidney disease (one nephrologist, Dr. Csaba Kovesdy and one pharmacist, Dr. Joanna Hudson) will explain the cardiovascular risks associated with discontinuing/reducing the dose of RAASi therapy due to hyperkalemia and the clinical evidence with novel potassium binders for reducing serum potassium and facilitating maintenance of RAASi therapy. Roles of specialty pharmacists in the management of patients with hyperkalemia will be identified, and clinical practice pearls will be described. A case presentation and faculty discussion of a patient with HF, CKD and hyperkalemia at high cardiorenal risk will provide attendees with best practices and key take-home messages.
This program is jointly provided by Postgraduate Institute for Medicine and Voxmedia LLC.

Click here for more information and to register

CO-CHAIRS
Joanna Hudson, PharmD, BCPS
Professor
Departments of Clinical Pharmacy and Translational Science & Medicine (Nephrology)
The University of Tennessee Health Science Center
Memphis, Tennessee

Robert Page, PharmD, MSPH, BCPS, BCGP
Professor
Departments of Clinical Pharmacy and Physical Medicine
Skaggs School of Pharmacy and Pharmaceutical Sciences
CU Anschutz
Aurora, Colorado

FACULTY
Stephen Greene, MD
Associate Professor of Medicine
Duke University School of Medicine
Duke Clinical Research Institute
Durham, North Carolina

Csaba Kovesdy, MD
Fred Hatch Professor of Medicine
University of Tennessee Health Science Center
Memphis VA Medical Center
Memphis, Tennessee

Educational Objectives:

• Recognize hyperkalemia as a frequent, treatable, and manageable side effect of optimal therapy for HF and CKD
• Explain the relationship between down-titration or discontinuation of RAASi therapy and clinical outcomes • Interpret the clinical evidence for novel potassium binders in the treatment of hyperkalemia
• Identify the multiple roles of the specialty pharmacist in managing the patient with HF and/or CKD with, or at high risk for hyperkalemia

Target Audience
This educational activity is intended for Pharmacists.

Educational Grant
Voxmedia International gratefully acknowledges the educational grant provided by AstraZeneca Pharmaceuticals.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008162-9999-25-091-L01-P)
Type of Activity: Knowledge